IRGD peptide

IRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.

Product Specifications

CAS Number

[1392278-76-0]

Product Name Alternative

C (CRGDKGPDC)

UNSPSC

12352209

Target

Integrin

Type

Peptides

Related Pathways

Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/iRGD_peptide.html

Purity

98.56

Solubility

H2O : ≥ 50 mg/mL

Smiles

O=C([C@@H](N)CSSC[C@H](NC1=O)C(O)=O)N[C@H](C(NCC(N[C@H](C(N[C@H](C(NCC(N2[C@H](C(N[C@H]1CC(O)=O)=O)CCC2)=O)=O)CCCCN)=O)CC(O)=O)=O)=O)CCCNC(N)=N

Molecular Formula

C35H57N13O14S2

Molecular Weight

948.04

References & Citations

[1]Puig-Saus C, et al. iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy. Gene Ther. 2014 Aug;21 (8) :767-74.|[2]Zhang L, et al. Combination of NRP1-mediated iRGD with 5-fluorouracil suppresses proliferation, migration and invasion of gastric cancer cells. Biomed Pharmacother. 2017 Sep;93:1136-1143.